[1] Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis, 1998, 27:1266-1277.
[2] Torre-Cisneros J, Doblas A, Aguado JM, et al.Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort.Clin Infect Dis, 2009, 48: 1657-1665.
[3] Meije Y,Piersimoni C,Torre-Cisneros J,et a1.Mycobacterial infections in solid organ transplant recipients.Clin Microbiol Infect,2014,20(Suppl7):89-101.
[4] Yehia BR, Bl umberg EA. Mycobacterium tuberculosisinfection in liver transplantation. Liver Transpl, 2010,16: 1129-1135.
[5] 王旭,陈虹,黄云帆,等. 利奈唑胺用于肝移植术后抗结核治疗一例临床分析. 中华移植杂志: 电子版,2014,8:28-30.
[6] Anger HA,Dworkin F,Sharma S,et al. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis,New York City,2000-06. J Antimicrob Chemother,2010,65:775-783. |
